about
Neonatal lupus: advances in understanding pathogenesis and identifying treatments of cardiac diseasePrevention and treatment in utero of autoimmune-associated congenital heart blockRelation of carotid plaque with natural IgM antibodies in patients with systemic lupus erythematosusCell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurementsAnti-C1q antibodies in systemic lupus erythematosus.Impaired clearance of apoptotic cardiocytes is linked to anti-SSA/Ro and -SSB/La antibodies in the pathogenesis of congenital heart block.A novel role of endothelin-1 in linking Toll-like receptor 7-mediated inflammation to fibrosis in congenital heart block.Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus.Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open-label clinical trial.Preferential transmission of genetic risk variants of candidate loci at 6p21 from asymptomatic grandparents to mothers of children with neonatal lupus.More to death than dying: apoptosis in the pathogenesis of SSA/Ro-SSB/La-associated congenital heart block.Serum Biomarkers of Inflammation, Fibrosis, and Cardiac Function in Facilitating Diagnosis, Prognosis, and Treatment of Anti-SSA/Ro-Associated Cardiac Neonatal Lupus.Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials.Finding the "PR-fect" solution: what is the best tool to measure fetal cardiac PR intervals for the detection and possible treatment of early conduction disease?Reactivity to the p305 Epitope of the α1G T-Type Calcium Channel and Autoimmune-Associated Congenital Heart BlockNeonatal lupus: basic research and clinical perspectives.The role of biomarkers in the assessment of lupus.Endosomal Toll-like receptors in clinically overt and silent autoimmunity.Brief report: enrichment of associations in genes with fibrosis, apoptosis, and innate immunity functions with cardiac manifestations of neonatal lupusAutoimmune associated congenital heart block: integration of clinical and research clues in the management of the maternal / foetal dyad at risk.Association of the idiotype:antiidiotype antibody ratio with the efficacy of intravenous immunoglobulin treatment for the prevention of recurrent autoimmune-associated congenital heart block.Disease progression in mothers of children enrolled in the Research Registry for Neonatal LupusTargeting downstream transcription factors and epigenetic modifications following Toll-like receptor 7/8 ligation to forestall tissue injury in anti-Ro60 associated heart block.Ro60 requires Y3 RNA for cell surface exposure and inflammation associated with cardiac manifestations of neonatal lupusDying right to live longer: positing apoptosis as a link between maternal autoantibodies and congenital heart block.Digestion of Chromatin in Apoptotic Cell Microparticles Prevents AutoimmunityReduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosusRecurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors.Assessment of fluorinated steroids to avert progression and mortality in anti-SSA/Ro-associated cardiac injury limited to the fetal conduction system.Updates on lupus and pregnancy.Doppler fetal mechanical PR interval prolongation with positive maternal anti-RNP but negative SSA/Ro and SSB/La auto-antibodies.Passively acquired anti-SSA/Ro antibodies are required for congenital heart block following ovodonation but maternal genes are not.Role of the urokinase plasminogen activator receptor in mediating impaired efferocytosis of anti-SSA/Ro-bound apoptotic cardiocytes: Implications in the pathogenesis of congenital heart block.A 2014 update on the management of patients with systemic lupus erythematosus.Cardiac Fibroblast Transcriptome Analyses Support a Role for Interferogenic, Profibrotic and Inflammatory Genes in Anti-SSA/Ro-Associated Congenital Heart Block.No histologic evidence of foetal cardiotoxicity following exposure to maternal hydroxychloroquine.Progress in the pathogenesis and treatment of cardiac manifestations of neonatal lupus.Single cell RNA sequencing to dissect the molecular heterogeneity in lupus nephritis.Ro52 autoantibodies arise from self-reactive progenitors in a mother of a child with neonatal lupus.Clinical and pathologic implications of extending the spectrum of maternal autoantibodies reactive with ribonucleoproteins associated with cutaneous and now cardiac neonatal lupus from SSA/Ro and SSB/La to U1RNP.
P50
Q27026064-0FB0CD66-B265-4570-BE85-88A9352E94C7Q27026699-99930BD7-672A-49E6-9266-38BE17AA42BAQ33799781-AD4081FD-624D-4916-9ECF-61776636F08BQ34478791-D262BC84-B427-457C-8912-E355A175F5D3Q34717540-672FCA65-28E1-4CCE-A16D-4C8D5CBF8FDBQ34945212-1549BC5F-E603-4D53-A7B4-CAA5675AEB88Q35182874-90368F0E-0DC8-424B-9B1C-4B1B6DE82DCAQ35501152-AB87C777-2368-46CE-ACFC-AE588F0B9609Q35546634-86A29254-3091-46C7-8E78-6DA2306A7113Q35722770-DAA0F1B9-DEBE-473E-B6FC-043BD7603CF4Q35839781-62840CCE-C9AF-4E65-A1F1-6342FB7B8892Q35985726-0C5F488F-C3AB-4259-8C59-5A87727483BDQ35986113-4D4ED23F-C52B-4C18-8570-60CDAA1D7C2AQ36095085-D4FC2C3C-9B43-4532-BF8F-CA63E1AC91C2Q36141367-10F88126-F519-4880-9098-E31A8462C49DQ36142480-F39B0A54-ADE0-4B75-A9F8-FC03F83CE4BDQ36252533-141CDA1B-FC07-4694-AB4E-4F7F62BB57E9Q36389926-19640AB2-07EA-4A74-AE79-2DA79674944BQ36522831-D616F19C-1838-4715-9E4F-9A1C0CD49FA2Q36551056-5E80FE61-563D-40F0-9660-82DB8C9E901BQ36551060-D491B186-D952-405D-BD7B-7F85FBB93D35Q36570978-85158C08-4CB3-4FC4-961A-C76DA6674228Q36577968-BCF89607-CE50-4183-9044-C2D30B794F5CQ37002424-CFE20491-EEB5-4824-B31E-BC973EE49CE1Q37077121-F72492CA-E1B5-4FB1-AE7C-DAFDD0380947Q37272155-0B7F2E24-857D-48FA-B863-34FF049A73E9Q37312374-2AA08611-8996-4268-9872-578BE6052146Q37393128-C1865F5F-AF88-488E-BF33-034B85A9462FQ37515813-4C3C0331-5DBD-431C-AE70-F957886165A6Q37522808-30E93865-862A-4CC5-9553-18D7626143CEQ37522813-03857C8C-E0A1-4065-BE5A-EABC2CBE5A01Q37596846-C693DF3D-C677-41BC-8AF6-6589FB60FC5EQ37632664-A7C84222-5D81-42C8-9AFF-21C2ABBB9284Q38273310-97827EB3-59A3-41FF-AC71-C26F6A245A4FQ38720234-A913C561-5F60-4DD8-9987-1EB3430281C8Q38734155-2B568086-A74C-4DF7-9071-988AF99D610EQ38777181-6C2835FC-0B05-4D19-986E-E1D1E056A076Q38806359-D7BD92BC-656A-4545-8DFE-1E58B1E5E1DFQ39001406-9EABF9BE-74FD-4993-AC0C-0A0BEC421798Q39435817-26F6E5A6-8CBE-4606-BD3F-5E1622F47B93
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Jill P Buyon
@en
Jill P Buyon
@nl
type
label
Jill P Buyon
@en
Jill P Buyon
@nl
prefLabel
Jill P Buyon
@en
Jill P Buyon
@nl
P31
P496
0000-0002-3852-7129